A360

KKE Mol. Hämatologie/Onkologie Also known as:A360; KKE Molekulare Hämatologie/Onkologie
IDI:(DE-He78)A360-20160331

Recent Publications

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors.
Nature biotechnology nn, nn () [10.1038/s41587-026-03152-x]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Review Article)  ;  ;  ;
(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary – Highlights from ESMO 2025 and the First International Cancer of Unknown Primary Meeting
Oncology research and treatment nn, nn () [10.1159/000551434]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients.
European journal of nuclear medicine and molecular imaging nn, nn () [10.1007/s00259-026-07916-0]  GO OpenAccess  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.
Blood cancer discovery 7(3), 479 - 495 () [10.1158/2643-3230.BCD-25-0062]  GO  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Review Article)  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.
Blood cancer discovery 7(2), 176-194 () [10.1158/2643-3230.BCD-25-0107]  GO  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.
Cancer cell 44(3), 604-623.e9 () [10.1016/j.ccell.2026.01.003]  GO OpenAccess  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
Leukemia 40(4), 730-738 () [10.1038/s41375-026-02889-3]  GO OpenAccess  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;
Familial colorectal cancer: search for novel predisposition genes.
Human genomics 20, 22 () [10.1186/s40246-025-00901-y]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Letter)  ;  ;  ;  ;  ;
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
Leukemia 40(2), 444-448 () [10.1038/s41375-025-02835-9]  GO OpenAccess  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Blood 147(10), 1098-1110 () [10.1182/blood.2025030816]  GO  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 


 Record created 2019-07-05, last modified 2022-03-18



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)